Autoregulation of the Raf-1 serine/threonine kinase

ανά Cutler, Richard E., Stephens, Robert M., Saracino, Misty R., Morrison, Deborah K.
Έκδοση 1998

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

ανά Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Τόπος έκδοσης Oncotarget (2017)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

ανά Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Τόπος έκδοσης Oncotarget (2019)

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells

ανά Booth, Laurence, Roberts, Jane L., Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Τόπος έκδοσης Cancer Biol Ther (2018)

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition

ανά Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Cutler, Richard E., Diala, Irmina, Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Τόπος έκδοσης Cancer Biol Ther (2018)

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

ανά Booth, Laurence, Roberts, Jane L., Samuel, Peter, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Τόπος έκδοσης Cancer Biol Ther (2018)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

ανά Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Kirkwood, John, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Τόπος έκδοσης Oncotarget (2017)

Neratinib augments the lethality of [regorafenib + sildenafil]

ανά Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Cutler, Richard E., Diala, Irmina, Lalani, Alshad S., Hancock, John F., Poklepovic, Andrew, Dent, Paul
Τόπος έκδοσης J Cell Physiol (2018)

Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies

ανά Ou, Ying, Xu, Yang, Gore, Lia, Harvey, R. Donald, Mita, Alain, Papadopoulos, Kyriakos P., Wang, Zhengping, Cutler, Richard E., Pinchasik, Dawn E., Tsimberidou, Apostolia M.
Τόπος έκδοσης Br J Clin Pharmacol (2018)

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

ανά Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Έκδοση 2013

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

ανά Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Τόπος έκδοσης Breast Cancer Res (2018)

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial

ανά Sudhan, Dhivya R., Schwarz, Luis J., Guerrero-Zotano, Angel, Formisano, Luigi, Nixon, Mellissa, Croessmann, Sarah, Ericsson, Paula I. González, Sanders, Melinda E., Balko, Justin M., Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Arteaga, Carlos L.
Τόπος έκδοσης Clin Cancer Res (2018)

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

ανά Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L.
Τόπος έκδοσης Clin Cancer Res (2018)

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

ανά Hanker, Ariella B., Brewer, Monica Red, Sheehan, Jonathan H., Koch, James P., Sliwoski, Gregory R., Nagy, Rebecca, Lanman, Richard, Berger, Michael F., Hyman, David M., Solit, David B., He, Jie, Miller, Vincent, Cutler, Richard E., Lalani, Alshad S., Cross, Darren, Lovly, Christine M., Meiler, Jens, Arteaga, Carlos L.
Τόπος έκδοσης Cancer Discov (2017)

Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers

ανά Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, Ericsson, Paula González, Servetto, Alberto, Rosario, Mariela H., Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Brewer, Monica R., Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.
Τόπος έκδοσης Cancer Cell (2020)

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

ανά Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, Ericsson, Paula González, Servetto, Alberto, Huerta-Rosario, Mariela, Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Brewer, Monica Red, Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.
Τόπος έκδοσης Cancer Cell (2020)

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

ανά Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Τόπος έκδοσης Sci Signal (2018)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

ανά Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.
Τόπος έκδοσης Nature (2018)